These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 24152907)
21. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group. Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137 [TBL] [Abstract][Full Text] [Related]
22. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915 [TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement. Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790 [No Abstract] [Full Text] [Related]
24. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Tanguy-Schmidt A; Rousselot P; Chalandon Y; Cayuela JM; Hayette S; Vekemans MC; Escoffre M; Huguet F; Réa D; Delannoy A; Cahn JY; Vernant JP; Ifrah N; Dombret H; Thomas X Biol Blood Marrow Transplant; 2013 Jan; 19(1):150-5. PubMed ID: 22960387 [TBL] [Abstract][Full Text] [Related]
25. First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis. Viganò I; Di Giacomo N; Bozzani S; Antolini L; Piazza R; Gambacorti Passerini C Am J Hematol; 2014 Oct; 89(10):E184-7. PubMed ID: 25041880 [TBL] [Abstract][Full Text] [Related]
26. Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Moon JH; Sohn SK; Lambie A; Ellis L; Hamad N; Uhm J; Gupta V; Lipton JH; Messner HA; Kuruvilla J; Kim D Biol Blood Marrow Transplant; 2014 Apr; 20(4):556-63. PubMed ID: 24447907 [TBL] [Abstract][Full Text] [Related]
27. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709 [TBL] [Abstract][Full Text] [Related]
28. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538 [TBL] [Abstract][Full Text] [Related]
29. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Ha HT; Lee JS; Urba S; Koenig RJ; Sisson J; Giordano T; Worden FP Thyroid; 2010 Sep; 20(9):975-80. PubMed ID: 20718683 [TBL] [Abstract][Full Text] [Related]
30. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy. Lazar J; Poonawalla T; Teng JM Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445 [TBL] [Abstract][Full Text] [Related]
31. Pneumatosis intestinalis and imatinib mesylate. O'Rafferty C; McElligott F; Storey L; O'Marcaigh A; Smith O Ann Hematol; 2014 Oct; 93(10):1783-4. PubMed ID: 24647683 [No Abstract] [Full Text] [Related]
32. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose. Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398 [TBL] [Abstract][Full Text] [Related]
33. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G; Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477 [TBL] [Abstract][Full Text] [Related]
34. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H; Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120 [TBL] [Abstract][Full Text] [Related]
35. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P; Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785 [TBL] [Abstract][Full Text] [Related]
36. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Giona F; Putti MC; Micalizzi C; Menna G; Moleti ML; Santoro N; Iaria G; Ladogana S; Burnelli R; Consarino C; Varotto S; Tucci F; Messina C; Nanni M; Diverio D; Biondi A; Pession A; Locatelli F; Piciocchi A; Gottardi E; Saglio G; Foà R Br J Haematol; 2015 Aug; 170(3):398-407. PubMed ID: 25891192 [TBL] [Abstract][Full Text] [Related]
37. Open-Label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Pediatric Patients with Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-Host Disease. Choi JY; Kim H; Baek HJ; Kook H; Lee JM; Kim BK; An HY; Hong KT; Shin HY; Kang HJ Transplant Cell Ther; 2021 Nov; 27(11):925.e1-925.e7. PubMed ID: 34314892 [TBL] [Abstract][Full Text] [Related]
38. Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: Real-life experience of the Spanish group of hematopoietic transplantation (GETH). Parra Salinas I; Bermudez A; López Corral L; Lopez Godino O; Móles-Poveda P; Martín G; Costilla Barriga L; Ferrá Coll C; Márquez-Malaver F; Ortí G; Zudaire Ripa MT; Rifon J; Martinez C; Clin Transplant; 2021 May; 35(5):e14255. PubMed ID: 33595866 [TBL] [Abstract][Full Text] [Related]
39. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651 [TBL] [Abstract][Full Text] [Related]
40. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Busca A; Locatelli F; Marmont F; Ceretto C; Falda M Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]